JPRN-UMIN000002779已完成2 期
Phase II clinial trial of Dasatinib for Imatinib resistant or refractory chronic myeloid leukemia in chronic phase. - Phase II trial of Dasatinib for Imatinib resistant/refractory CML in CP.
Ph Leukemia Trial Group0 个研究点目标入组 120 人开始时间: 2009年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are true with either of the followings are excluded; @Females in childbearing years with no will or capability to use appropriate birth control during the trial. @Females during pregnancy or lactation. @Male patients with no will or capability to use appropriate birth control during the trial. @Past history or concomitant cardiovascular diseases that are serious or poorly-controlled. @Other serious past disease history or present concomitant diseases that are considered inappropriate to condcut this trial. @Active infectious diseases, or Other malignancies, or HBV/HIV infection. @Pasthistory of Dasatinib therapy.
研究者
相似试验
招募中
2 期
Phase II clinical trial of low dose dasatinib in patients with resistant or intolerant chronic myeloid leukemia who are treated with low lose imatinibChronic myeloid leukemia patients in chronic phase who are refractory or resistant to low dose imatinib therapy.JPRN-UMIN000003499Kanto CML Study Group30
已完成
2 期
Phase II clinical trial of dasatinib in newly diagnosed chronic phase chronic myelogenous leukemianewly diagnosed chronic myelogenous leukemia in chronic phaseJPRN-UMIN000006346Ph leukemia trial Group50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-GBEBMT (European group for Blood and Marrow Transplantation)50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow TransplantatioEUCTR2008-001361-29-FREBMT (European group for Blood and Marrow Transplantation)50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-DEEBMT (European group for Blood and Marrow Transplantation)50